Australia markets closed

Genprex Inc (2DE.MU)

Munich - Munich Delayed price. Currency in EUR
Add to watchlist
0.18230.0000 (0.00%)
As of 08:03AM CET. Market open.
Full screen
Previous close0.1823
Open0.1823
Bid0.0000 x N/A
Ask0.0000 x N/A
Day's range0.1823 - 0.1823
52-week range0.1600 - 66.1600
Volume300
Avg. volume16
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings date31 Mar 2024 - 05 Apr 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • PR Newswire

    Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators

    Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the expansion of its nonclinical programs into new indications through Sponsored Research Agreements and Material Transfer Agreements with multiple academic research collaborators to study TUSC2, the tumor suppressor gene used in Genprex's lead drug candidate, REQORSA (quaratusugene ozeplasmid), and N

  • PR Newswire

    Genprex to Present at Upcoming BIO CEO & Investor Conference

    Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its Chief Financial Officer, Ryan Confer, will be providing an overview of the Company's gene therapies for cancer and diabetes at the upcoming BIO CEO & Investor Conference.

  • PR Newswire

    Genprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa® Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer

    Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that in January 2024, the first patient was enrolled and dosed in the Phase 2a expansion portion of the Company's Acclaim-1 clinical study of Reqorsa® Therapy (quaratusugene ozeplasmid) in combination with AstraZeneca's Tagrisso® to treat patients with late-stage non-small cell lung cancer (NSCLC).